Introduction
Materials and methods
Collection of patient samples and clinical data
Baseline | 6 months | |
---|---|---|
DAS28CRP
| 5.7 (5.1-6.5) | 2.1 (1.8-2.8) |
Swollen joint count (0-28)
| 10 (7.0-17) | 0 (0-0) |
Tender joint count (0-28)
| 12 (7.0-18) | 0 (0-1.3) |
Swollen joint count (0-40)
| 13 (9.0-22) | 0 (0-0) |
Tender joint count (0-40)
| 17 (11-26) | 0 (0-3.0) |
VAS doctor global (0-100 mm)
| 56 (41-73) | 2.0 (0-10) |
CRP (mg/ml)
| 15 (7.0-42) | 7.0 (7.0-7.0) |
SDAI (0.7-82)
| 37 (29-47) | 3.1 (0.86-7.0) |
IgM-RF (% positive)
| 70.7% | - |
Anti-CCP (% positive)
| 62.7% | - |
TSS (% positive)
| 17.3% | - |
ELISA
Statistics
Results
Plasma levels of CXCL13 in early RA
Additional adalimumab treatment resulted in a greater degree of CXCL13 inhibition
CXCL13 was associated with core disease parameters
Time | Disease marker | 0 months rho (P) | 6 months rho (P) |
---|---|---|---|
Baseline
| |||
IgM-RF | -0.112 (0.34) | 0.073 (0.54) | |
Anti-CCP | 0.021 (0.86) | 0.099 (0.31) | |
TSS | -0.011 (0.92) | 0.059 (0.62) | |
Swollen joint count 28
|
0.336 (0.003)
| 0.110 (0.35) | |
Tender joint count 28 | 0.166 (0.16) | 0.001 (0.99) | |
Swollen joint count 40
|
0.392 (0.001)
| 0.177 (0.13) | |
Tender joint count 40 | 0.162 (0.17) | 0.007 (0.95) | |
VAS doctor global
|
0.378 (0.001)
| 0.103 (0.38) | |
CRP | 0.094 (0.42) | 0.145 (0.21) | |
DAS28CRP | 0.205 (0.078) | 0.089 (0.45) | |
SDAI
|
0.254 (0.028)
| 0.091 (0.44) | |
12 months
| |||
Swollen joint count 28 | 0.131 (0.27) | -0.077 (0.51) | |
Tender joint count 28 | 0.195 (0.096) | -0.012 (0.92) | |
Swollen joint count 40 | 0.162 (0.17) | -0.085 (0.47) | |
Tender joint count 40 | 0.219 (0.060) | 0.045 (0.71) | |
VAS doctor | 0.006 (0.96) | -0.037 (0.76) | |
CRP | -0.047 (0.69) | -0.124 (0.30) | |
DAS28CRP | 0.059 (0.62) | 0.012 (0.92) | |
SDAI | 0.009 (0.94) | 0.047 (0.67) |
High baseline CXCL13 in the DMARD-treated group was associated with low SDAI and VAS score at one year
Sustained remission after 2 years was associated with high baseline CXCL13
DMARD + ADA | DMARD | |||
---|---|---|---|---|
CXCL13-high | CXCL13-low | CXCL13-high | CXCL13-low | |
Additional treatment | 6/27, 22.2% | 4/10, 40% | 9/23, 39,1% | 6/16, 37,5% |